HUTCHMED (China) Limited Starts Phase I Trial of KRAS-EGFR ATTC HMPL-A830

HUTCHMED initiated the Phase Ia part of a global first-in-human trial of KRAS-EGFR ATTC HMPL-A830 in advanced solid tumors, with first dosing on Sept. 24, 2026 in China. A GSK subsidiary holds rights ex-Mainland China, Hong Kong, Macau and Taiwan, subject to closing conditions.Material DetailsConte…